Recruiting studies: Membranoproliferative Glomerulonephritis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
Phase 3 · 131 location(s) · Novartis Pharmaceuticals · NCT05755386 Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
Phase 3 · 9 location(s) · Novartis Pharmaceuticals · NCT05795140 Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
Phase 2 · 4 location(s) · Region Skane · NCT04183101 Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
NA · 1 location(s) · Mario Negri Institute for Pharmacological Research · NCT05996731 Chinese Adults With Kidney Disease
Phase 2 · 9 location(s) · ADARx Pharmaceuticals, Inc. · NCT07522099 A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy
Phase N/A · 3 location(s) · Novartis Pharmaceuticals · NCT07416162 Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
Phase 3 · 53 location(s) · Novartis Pharmaceuticals · NCT03955445 National Registry of Rare Kidney Diseases
Phase N/A · 1 location(s) · UK Kidney Association · NCT06065852

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.